Table 1.
Baseline characteristics.
| Control Period, (March–April 2019, n=145) | First Wave, (March–April 2020, n=108) | Second Wave, (July–August 2020, n=82) | |
|---|---|---|---|
| Age (yr)∗ | 65.7±15.2 | 64.1±14.5 | 63.8±14.09 |
| Gender (male) | 98 (67.6%) | 76 (70.4%) | 60 (73.2%) |
| Hypertension | 95 (65.5%) | 72 (66.7%) | 48 (58.5%) |
| Dyslipidaemia | 99 (68.3%) | 81 (75.0%) | 54 (65.9%) |
| Diabetes | 63 (43.5%) | 42 (38.9%) | 27 (32.9%) |
| Previous percutaneous coronary intervention | 33 (22.8%) | 29 (26.9%) | 8 (9.8%) |
| Previous coronary artery bypass graft | 4 (2.8%) | 3 (2.8%) | 2 (2.4%) |
| Stroke/TIA | 11 (7.6%) | 5 (4.6%) | 2 (2.4%) |
| Peripheral vascular disease | 8 (5.5%) | 2 (1.9%) | 3 (3.7%) |
| Obesity (BMI≥35) | 20 (13.8%) | 11 (10.2%) | 4 (4.9%) |
| Admission medications | |||
| Single antiplatelet | 34 (23.5%) | 23 (21.3%) | 21 (25.6%) |
| Dual antiplatelet | 20 (13.8%) | 23 (21.3%) | 3 (3.7%) |
| Statin | 63 (43.5%) | 53 (49.1%) | 26 (31.7%) |
| ACE-I/ARB/ARNI | 67 (46.2%) | 55 (50.1%) | 26 (21.7%) |
Median ± Std deviation.
Abbreviations: ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor-neprilysin inhibitor; BMI, body mass index; TIA, transient ischaemic attack.